SAN FRANCISCO, CA--(Marketwired - Apr 8, 2013) - Immunovative, Inc. ("IMUN" or the "Company") (OTCQB: IMUN) has today announced that its name and trading symbol changes to Tauriga Sciences, Inc. and (OTCQB: TAUG) respectively, will be effective at market open on Tuesday, April 09, 2013 ("tomorrow"). The Company was notified this morning by FINRA that this corporate action ("name and symbol change") was approved and that the name and symbol change will be announced today (04/08/2013) on FINRA's Daily List. The Company's transfer agent (Clear Trust Transfer) is aware of the corporate action and all previous stock certificates will be automatically processed into shares of Tauriga Sciences, Inc.
Tauriga Sciences Inc. CEO Seth M. Shaw stated, "The Company is pleased to have enacted this name and symbol change to better reflect the future direction and nature of the Company. The Company and its management are work diligently to create shareholder by taking advantage of the significant opportunities available to us in life sciences space. Management greatly appreciates the extraordinary level shareholder support that it has received over the previous months and is committed to building a innovative and successful Company in the future."
The Company's new corporate website is currently under development and a press release will be issued to shareholders to notify the public of the upcoming launch date; the new URL address will be www.taurigasciences.com
About Tauriga Sciences, Inc.:
Tauriga Sciences Inc. ("the Company") is a holding company that operates in the biotechnology space, which includes medical devices and development of proprietary drug compounds. The mission of the Company is to acquire a diversified portfolio of medical technologies with the aim of providing financial and human capital resources, to unlock significant value for the shareholders. The Company's business model entails the acquisition of licenses, equity stakes, rights on both an exclusive and non-exclusive basis, and entire businesses. Management is firmly committed to building lasting shareholder value in the short, intermediate, and long terms. The Company's new corporate website can be found at URL address (www.taurigasciences.com).
DISCLAIMER:
Forward-Looking Statements: Except for statements of historical fact, this news release contains certain "forward-looking statements" as defined by the Private Securities Litigation Reform Act of 1995, including, without limitation expectations, beliefs, plans and objectives regarding the development, use and marketability of products. Such forward-looking statements are based on present circumstances and on IMUN's predictions with respect to events that have not occurred, that may not occur, or that may occur with different consequences and timing than those now assumed or anticipated. Such forward-looking statements involve known and unknown risks, uncertainties and other factors, and are not guarantees of future performance or results and involve risks and uncertainties that could cause actual events or results to differ materially from the events or results expressed or implied by such forward-looking statements. Such factors include general economic and business conditions, the ability to successfully develop and market products, consumer and business consumption habits, the ability to fund operations and other factors over which IMUN has little or no control. Such forward-looking statements are made only as of the date of this release, and IMUN assumes no obligation to update forward-looking statements to reflect subsequent events or circumstances. Readers should not place undue reliance on these forward-looking statements. Risks, uncertainties and other factors are discussed in documents filed from time to time by IMUN with the Securities and Exchange Commission.
Contact:
For more information please contact:
Mr. Seth M. Shaw
Chairman & Chief Executive Officer
Tauriga Sciences, Inc. (Formerly Known as: Immunovative, Inc.)
New York: +1-917-796-9926
Montreal: +1-514-840-3697
Email: sethsms47@aol.com
View More
View More
test123 kjk
